ZYBERNO
Stock Report
Updated Sep 1, 2026

VIVOS INC. (RDGL)

Healthcare • OTC

$0.05

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
28.0/100
POOR BUSINESS
VIVOS INC. (RDGL) scores 28/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-154.9%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.07x)
Operating Margin (Operational Efficiency):CRITICAL (-2,852.5%)
Return on Capital (Capital Efficiency):CRITICAL (-405.6%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

VIVOS INC. (RDGL) stock report — Zyberno Score 28/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.05
Market Cap:$25.12M

Valuation Multiples (3)

P/B Ratio:9.12x
P/S Ratio:253.52x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$22.89M

Price Action & Momentum (3)

Momentum Percentile:10 / 100
% of 52-Week High:41.2%
B. Profitability Assessment

Return Metrics (5)

ROA:-144.1%
Reinvestment Rate:-4.9%
Fundamental Growth Rate (g):19.7%

Margin Analysis (3)

Operating Margin Ttm:-2,852.5%
Net Margin Ttm:-3,633.6%
Ebitda Margin:-2,852.1%

TTM Performance (3)

Gross Margin Ttm:-25.9%
Operating Margin Ttm:-2,852.5%
Net Margin Ttm:-3,633.6%

Yield Metrics (2)

Earnings Yield:-$18.43
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (2)

Latest Earnings Filed:2026-08-12

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):31.6%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:48.85x
Quick Ratio:47.72x
Cash Ratio:46.75x

Leverage Analysis (3)

Debt To Equity Ttm:0.07x
Debt-to-Equity Ratio:0.07x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-43.03x
Times Interest Earned:-43.03

Capital Structure (4)

Working Capital:2,391,000.00
Cash And Cash Equivalents:2,336,022.00
Long Term Debt:$73.98K
Net Debt:-$2.23M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $99.10K
Linear Growth: 31.6%
📊 Click to view full RDGL Revenue analysis & methodology →
Cost Of Revenue Ttm:$124.76K

Profitability Breakdown (2)

Gross profit TTM: -$25.66K
Linear Growth: -50.0%
📊 Click to view full RDGL Gross Profit analysis & methodology →
-$2.83M

Bottom Line Performance (3)

-$3.60M
Income Before Tax:-$3.60M
Ebitda Ttm:-2,826,390.00

Operating Expenses (5)

Operating Expenses:2,801,107.00
R And D Expense:212,091.00
Sga Expense:304,403.00
Income Tax Expense:$0.00
Interest Expense:73,550.00

Expense Ratios (3)

R And D To Revenue Percentage:582.7%
Sga To Revenue Percentage:836.3%
Ebitda Margin:-2,852.1%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$2.88M
Current Assets:$2.44M
Ppe Net:338,236.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:123,955.00
Current Liabilities:49,973.00
Long Term Debt:$73.98K
Short Term Debt:$29.17K

Equity & Capital (3)

Equity:$2.76M
Retained Earnings:-$90.44M
Common Stock:950,000,000.00

Working Capital Items (3)

Accounts Receivable:15,650.00
Inventory:56,427.00
Accounts Payable:20,802.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$2.03M-$2.16M

Investment Activities (1)

Investing Cash Flow:-$151.21K

Financing Activities (3)

Financing Cash Flow:$1.55M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:130,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.01
-$0.01
Earnings Per Share Ttm:-$0.01

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.00
Operating Cash Flow Per Share:-$0.00

Book Value & Capital (2)

Book Value Per Share:$0.01
Cash Per Share:0.00

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.04x
Working Capital Turnover Ttm:0.04x

Receivables Management (2)

Receivables Turnover Ttm:6.33x
Days Sales Outstanding Ttm:57.64

Inventory Management (2)

Inventory Turnover Ttm:2.21x
Days Inventory Outstanding Ttm:165.09

Payables & Cash Cycle (2)

Days Payable Outstanding:60.86
Cash Conversion Cycle:161.87
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-4.9%
Fundamental Growth Rate (g):19.7%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):31.6%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-50.0%
Book Value Growth Rate (Linear):20.7%
C. Company Profile & Context

Corporate Information (6)

Symbol:RDGL
Company Name:VIVOS INC.
Sector:Healthcare
Industry:Medical Devices
Exchange:OTC
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:490.70M
Shares Outstanding Basic:490.70M
Shares Outstanding Diluted:490.70M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 08:10:56 UTC
Data Timestamp:2026-08-20T20:56:51.333944
Scroll to Top